In this webinar, Dr. Georgiev will discuss progress toward developing and validating integrated platforms for antibody discovery. He will highlight how these approaches can transform both the process and cost of identifying new monoclonal antibody drug candidates, while enabling the discovery of antibody phenotypes that have been challenging or even impossible to achieve using traditional methods.